slc38a6 Antibody

What is SLC38A6 and what is its biological function?

SLC38A6, also known as SNAT6 (Sodium-coupled Neutral Amino Acid Transporter 6), is a member of the solute carrier family involved in amino acid transport across cellular membranes. This protein plays a crucial role in various biological processes including protein synthesis, cell growth, and nutrient sensing. SLC38A6 functions as a carrier of nutrients for cells, particularly neurons and macrophages, enabling them to perform their specific functions. The dysregulation of SLC38A6 has been linked to metabolic disorders and cancer progression, making it a promising target for therapeutic interventions .

SLC38A6 is also known by other names including N-system amino acid transporter NAT-1 (NAT1) and functions primarily to transport neutral amino acids in a sodium-dependent manner . This transport function is essential for maintaining cellular homeostasis and supporting various physiological processes that depend on amino acid availability.

What types of SLC38A6 antibodies are available for research?

Several types of SLC38A6 antibodies are available for research purposes, primarily polyclonal antibodies derived from rabbits. These include:

These antibodies are typically available in liquid form, preserved in buffers containing glycerol and stabilizing agents, and have undergone purification methods such as Protein G purification to ensure >95% purity . The polyclonal nature of these antibodies allows for recognition of multiple epitopes on the SLC38A6 protein, increasing sensitivity for detection applications.

What is the expected molecular weight of SLC38A6 protein and how is this relevant for antibody validation?

When validating SLC38A6 antibodies, researchers should expect to see bands at the appropriate molecular weight in membrane fractions but not in soluble cytosolic fractions, as SLC38A6 is a membrane protein. This pattern has been experimentally confirmed through 2D gel analyses where SLC38A6 was only found in the insoluble fraction at a size between 37 and 50 kDa . The absence of bands in the soluble fraction and the presence of a single band of the expected size in the membrane fraction strongly suggests antibody specificity.

Which experimental applications have SLC38A6 antibodies been validated for?

SLC38A6 antibodies have been validated for multiple experimental applications, with specific protocols and parameters established for optimal results:

These applications have been successfully employed in studies investigating SLC38A6 expression in various tissues, particularly in neuronal cells and macrophages . The versatility of these applications allows researchers to study SLC38A6 at multiple levels, from protein expression to cellular localization and protein-protein interactions.

What are the recommended protocols for using SLC38A6 antibodies in Western blot analysis?

For Western blot analysis of SLC38A6, researchers should follow these methodological steps:

• Sample Preparation: For membrane proteins like SLC38A6, extraction should focus on the insoluble fraction. Separate proteins into insoluble and soluble fractions from tissue or cell lysates.

• Protein Separation: Use SDS-PAGE to separate proteins. SLC38A6 has been successfully detected on Immobilon-P PVDF membranes from 2D gels.

• Membrane Blocking: Pre-block membranes for 1 hour in blocking buffer containing 5% nonfat dry milk diluted in buffer (1.5 M NaCl, 0.1 M Tris, 0.05% Tween 20, pH 8.0).

• Primary Antibody Incubation: Apply SLC38A6 antibody at dilutions of 1:1000-1:5000 (for PACO37902) or as specifically recommended by the manufacturer. Incubate overnight at 4°C.

• Secondary Antibody Application: After washing, incubate with horseradish peroxidase-conjugated secondary antibody (typically goat anti-rabbit at 1:10000 dilution) for 1 hour.

• Detection: Use enhanced chemiluminescent (ECL) method for detection.

• Expected Results: Look for bands between 37-50 kDa, corresponding to the SLC38A6 protein. In some experiments, bands at 51 kDa and 33 kDa have been observed .

This protocol has been successfully used to confirm the expression of SLC38A6 as a membrane protein in mouse brain samples, with the antibody showing specificity through the absence of signals in the soluble fraction .

How should SLC38A6 antibodies be used for immunofluorescence and immunohistochemistry studies?

For immunofluorescence and immunohistochemistry studies using SLC38A6 antibodies, researchers should follow these methodological guidelines:

• Tissue Preparation: For paraffin-embedded sections, standard deparaffinization and antigen retrieval procedures should be followed. Section thickness of approximately 7 μm has been effective.

• Antibody Dilution: Use SLC38A6 antibodies at dilutions of 1:50-1:200 for immunofluorescence applications. For the Sigma-Aldrich HPA018508 antibody, a 1:200 dilution has been reported effective.

• Incubation Conditions: Incubate sections with the SLC38A6 primary antibody (and any co-staining markers) diluted in a suitable buffer (e.g., Tris-buffered saline with 0.25% gelatin, 0.5% Triton X-100) overnight at 4°C.

• Secondary Antibody: For fluorescent detection, use appropriate secondary antibodies such as anti-rabbit-488 (diluted 1:400).

• Nuclear Counterstaining: DAPI can be used for nuclear counterstaining to provide cellular context.

• Imaging: Fluorescence microscopy (40X and 10X magnifications have been used effectively) or confocal microscopy (63X magnification) for higher resolution imaging.

• Co-localization Studies: For determining cellular expression patterns, co-staining with cell-type specific markers is recommended (e.g., NeuN for neurons, GFAP for astrocytes, PAG for glutamatergic interneurons) .

This approach has been successfully used to demonstrate that SLC38A6 is primarily expressed in excitatory neurons with some minor expression in inhibitory neurons, while being absent in astrocytes .

How can researchers validate the specificity of SLC38A6 antibodies?

Validating the specificity of SLC38A6 antibodies is crucial for experimental reliability. Researchers should consider the following methodological approaches:

• Fractional Protein Analysis: Separate proteins into membrane (insoluble) and cytosolic (soluble) fractions. SLC38A6, being a membrane protein, should only be detected in the insoluble fraction at the expected molecular weight (37-50 kDa).

• Knockout Controls: When available, use tissue or cells from SLC38A6 knockout models as negative controls. Both systemic and conditional knockouts (e.g., Lyz-CRE specific) have been used in research .

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide before application to samples. This should abolish or significantly reduce specific binding.

• Multiple Antibody Comparison: Use different antibodies targeting distinct epitopes of SLC38A6 to confirm consistent staining patterns.

• Overexpression Systems: Utilize cells overexpressing SLC38A6 (e.g., via lentiviral vectors as described in the literature with pLJM-hSLC38A6-v2) as positive controls .

• Expected Cellular Distribution: Confirm that the staining pattern aligns with known subcellular localization (membrane) and tissue distribution (neurons rather than glial cells) .

These validation methods have been employed in published research to confirm antibody specificity, particularly highlighting the absence of unspecific bands in protein fractions and the expected cellular expression patterns .

Which cell types express SLC38A6 and how can this be experimentally determined?

SLC38A6 exhibits a specific cellular expression pattern that has been determined through various experimental approaches. The following cell types have been identified as expressing SLC38A6:

• Excitatory Neurons: SLC38A6 is predominantly expressed in excitatory neurons in the brain, as demonstrated by co-localization with neuronal markers such as NeuN .

• Inhibitory Neurons: Some minor expression has been detected in inhibitory neurons, though at lower levels than in excitatory neurons .

• Monocytes/Macrophages: Recent research has shown SLC38A6 expression in monocytes and macrophages, with upregulation during inflammatory conditions such as pneumonia and sepsis .

• Not Expressed in Astrocytes: Importantly, SLC38A6 is not expressed in glial cells/astrocytes, as demonstrated by the absence of co-localization with GFAP .

To experimentally determine SLC38A6 expression in specific cell types, researchers should employ:

• Co-localization Immunofluorescence: Using SLC38A6 antibodies alongside cell-type-specific markers (NeuN for neurons, GFAP for astrocytes, PAG for glutamatergic interneurons).

• Quantitative Analysis: Counting the number of cells positive for both SLC38A6 and cell-type markers compared to the total cell count (DAPI-stained nuclei).

• Flow Cytometry: For immune cells such as monocytes/macrophages, flow cytometry can be used to correlate SLC38A6 expression with specific cell populations .

• Conditional Knockout Models: Using cell-type-specific Cre-recombinase systems (e.g., Lyz-CRE for myeloid cells) to confirm functional significance in specific cell populations .

These approaches have revealed that SLC38A6 has cell-type specific expression patterns that correlate with its functional roles in amino acid transport and cellular metabolism.

How is SLC38A6 distributed subcellularly and what methods best visualize this distribution?

SLC38A6 shows specific subcellular distribution patterns that reflect its function as a membrane transporter. The following describes its subcellular localization and methods to visualize it:

Subcellular Distribution:

• Plasma Membrane: As an amino acid transporter, SLC38A6 is primarily localized to the plasma membrane, confirmed by its detection in membrane protein fractions but not in soluble cytosolic fractions .

• Proximity to Synaptic Proteins: SLC38A6 shows interaction with synaptic proteins such as Snap25 and Synaptotagmin, suggesting localization near synaptic structures in neurons .

Visualization Methods:

• Confocal Microscopy: High-resolution confocal microscopy (63X magnification) provides detailed visualization of SLC38A6 subcellular distribution .

• Proximity Ligation Assay (PLA): This technique has been employed to demonstrate the interaction between SLC38A6 and synaptic proteins, revealing its proximity to synaptic structures. PLA signals are detected with red filters, and quantification of signals per cell provides a measure of protein interactions .

• Subcellular Fractionation: Biochemical separation of cellular components followed by Western blotting can confirm the membrane localization of SLC38A6. 2D gel electrophoresis followed by immunoblotting has shown SLC38A6 exclusively in the insoluble (membrane) fraction .

• Co-localization with Membrane Markers: Fluorescence imaging with membrane markers or tagged membrane proteins can help visualize SLC38A6's membrane localization.

• GFP-Tagged Expression Systems: For live-cell imaging, expression of GFP-tagged SLC38A6 can help track its dynamic localization and trafficking.

These methodological approaches have collectively established SLC38A6 as a membrane protein with specific subcellular distribution patterns relevant to its function in amino acid transport .

What methods are most effective for studying SLC38A6 interactions with other proteins?

Several methodological approaches have proven effective for studying SLC38A6 interactions with other proteins:

• Proximity Ligation Assay (PLA): This technique has been successfully applied to investigate interactions between SLC38A6 and synaptic proteins like Snap25 and Synaptotagmin. The method allows visualization of protein-protein interactions that occur within 40 nm distance. The following quantitative data demonstrates these interactions:

  Protein Interaction	PLA Signals per Cell
  Synaptotagmin-Synaptotagmin	~15 signals
  Snap25-Snap25	~12 signals
  Synaptotagmin-Snap25	~10 signals
  SLC38A6-Synaptotagmin	~8 signals
  SLC38A6-Snap25	~6 signals

  This quantification reveals significant interactions between SLC38A6 and synaptic proteins, suggesting functional associations .

• Co-immunoprecipitation: Although not explicitly described in the provided sources, co-immunoprecipitation using SLC38A6 antibodies followed by mass spectrometry or Western blotting can identify binding partners.

• Two-Hybrid System: Yeast or mammalian two-hybrid systems can be employed to screen for potential protein interactions.

• FRET/BRET Analysis: Fluorescence or bioluminescence resonance energy transfer techniques can assess protein interactions in living cells by measuring energy transfer between fluorophores or luminescent tags attached to potential interacting proteins.

• Crosslinking Followed by Mass Spectrometry: Chemical crosslinking of proteins in their native environment followed by mass spectrometry analysis can identify interaction partners.

The PLA method has been particularly valuable in establishing SLC38A6's interactions with synaptic proteins, revealing its proximity to membrane and vesicular proteins . These interactions may have functional significance for the role of SLC38A6 in neuronal function and amino acid transport.

How is SLC38A6 expression altered in disease states and what methods detect these changes?

Research has identified significant alterations in SLC38A6 expression in several disease states, particularly in inflammatory conditions:

• Pulmonary Inflammation/Pneumonia:

  • SLC38A6 expression is upregulated in the blood of pneumonia patients

  • This upregulation correlates positively with monocyte numbers and white blood cell counts

  • Similar upregulation is observed in LPS-induced sepsis mouse models

• Inflammatory Macrophage Activation:

  • Increased SLC38A6 expression is observed in activated macrophages during inflammation

  • This upregulation appears to be dependent on Toll-like receptor 4 (TLR4) signaling

Methodological Approaches for Detecting Expression Changes:

• qRT-PCR: For measuring mRNA expression levels of SLC38A6 in patient samples or experimental models.

• Western Blotting: To quantify protein expression changes, with appropriate housekeeping protein controls for normalization.

• Flow Cytometry: Particularly useful for analyzing SLC38A6 expression in specific immune cell populations such as monocytes/macrophages.

• Correlation Analysis: Statistical methods to correlate SLC38A6 expression with clinical parameters such as blood cell counts or inflammatory markers.

• Experimental Models: LPS-induced sepsis models in mice have been used to study SLC38A6 expression changes under inflammatory conditions.

• Inhibitor Studies: Using signaling pathway inhibitors (e.g., TAK242 for TLR4 inhibition) to investigate regulatory mechanisms of SLC38A6 expression .

These findings suggest that SLC38A6 expression changes may serve as potential biomarkers for inflammatory conditions and could provide insights into disease mechanisms involving altered amino acid transport.

What is the role of SLC38A6 in pulmonary inflammation and macrophage function?

SLC38A6 plays a significant role in pulmonary inflammation through its actions in macrophages, as demonstrated by recent research:

• Promotion of Inflammatory Activation:

  • SLC38A6 upregulation in monocytes/macrophages promotes their activation during pulmonary inflammation

  • This activation leads to increased production of pro-inflammatory cytokines, particularly TNF-α and IL-1β

• Functional Impact Demonstrated through Knockout Models:

  • Both systemic SLC38A6 knockout and myeloid-specific knockout (using Lyz-CRE) mice show:

    • Reduced severity of LPS-induced sepsis

    • Decreased levels of pro-inflammatory cytokines TNF-α and IL-1β in serum

    • Lower numbers of monocytes in bronchial alveolar lavage and peritoneal lavage

• Relationship with TLR4 Signaling:

  • SLC38A6 upregulation appears to be dependent on TLR4 signaling

  • Blocking TLR4 signaling with TAK242 leads to downregulation of SLC38A6

  • Similar results were observed in TLR4 knockout macrophages

  • Importantly, in macrophages with overexpressed SLC38A6, blocking TLR4 signaling only partially reduced IL-1β expression (by ~80%), indicating that SLC38A6 itself participates in the IL-1β expression process

• Mechanistic Role as Amino Acid Transporter:

  • As a carrier of nutrients (amino acids) for macrophages, SLC38A6 likely supports the metabolic requirements needed for inflammatory activation

  • This suggests a link between cellular metabolism and inflammatory function in macrophages

These findings establish SLC38A6 as an important player in macrophage-mediated pulmonary inflammation, with implications for understanding inflammatory disease mechanisms and potential therapeutic targeting.

How might targeting SLC38A6 provide therapeutic benefits in inflammatory conditions?

Research suggests several potential therapeutic avenues related to SLC38A6 in inflammatory conditions:

• Reduction of Inflammatory Severity:

  • Knockout studies have demonstrated that either systemic or myeloid-specific deletion of SLC38A6 alleviates the severity of sepsis in mouse models

  • This suggests that inhibiting SLC38A6 function could potentially reduce inflammatory damage in conditions like pneumonia or sepsis

• Decrease in Pro-inflammatory Cytokine Production:

  • SLC38A6 deficiency leads to reduced levels of TNF-α and IL-1β, key mediators of inflammatory damage

  • Targeting SLC38A6 could therefore provide a mechanism to modulate cytokine responses without completely suppressing immune function

• Possible Therapeutic Strategies:

  • Small molecule inhibitors of SLC38A6 transport function

  • Antisense oligonucleotides or siRNA to reduce SLC38A6 expression

  • Peptide-based inhibitors targeting the transporter's active site

  • Antibody-based approaches to modulate SLC38A6 function

• Selective Targeting of Inflammatory Macrophages:

  • Since SLC38A6 is upregulated specifically in activated macrophages during inflammation, targeting this protein might allow selective modulation of inflammatory macrophages while sparing homeostatic functions

  • This could potentially result in fewer side effects compared to broader immunosuppressive approaches

• Potential Diseases for Therapeutic Application:

  • Acute pulmonary inflammation/pneumonia

  • Sepsis and septic shock

  • Potentially other inflammatory conditions where macrophage activation plays a key role

Researchers conclude that "SLC38A6 might be a promising target molecule for pulmonary inflammation treatment," based on its role in promoting macrophage activation and the beneficial effects observed in knockout models . This represents a novel approach to inflammatory disease treatment by targeting amino acid transport mechanisms that support inflammatory cell metabolism.

How can researchers address cross-reactivity issues with SLC38A6 antibodies?

When working with SLC38A6 antibodies, cross-reactivity can pose challenges for experimental interpretation. Researchers can address these issues through several methodological approaches:

• Comprehensive Validation Protocol:

  • Begin with rigorous antibody validation using both positive controls (tissues known to express SLC38A6) and negative controls (knockout tissues or cells where available)

  • Perform peptide competition assays to confirm specificity

  • Test antibodies across multiple applications (WB, IF, IHC) to confirm consistent results

• Subcellular Fractionation Approach:

  • Utilize the membrane localization of SLC38A6 as a validation criterion

  • Separate proteins into membrane (insoluble) and cytosolic (soluble) fractions

  • SLC38A6 should only be detected in the membrane fraction at the expected molecular weight

  • The absence of signal in the cytosolic fraction provides strong evidence for specificity

• Dilution Optimization:

  • Optimize antibody dilutions for each specific application

  • For commercial antibodies, use the manufacturer's recommended ranges as starting points:

    • ELISA: 1:2000-1:10000

    • Western blot: 1:1000-1:5000

    • Immunofluorescence: 1:50-1:200

  • Perform titration experiments to find the optimal signal-to-noise ratio

• Multiple Antibody Approach:

  • When possible, use multiple antibodies raised against different epitopes of SLC38A6

  • Consistent results across different antibodies provide stronger evidence for specificity

• Genetic Approaches for Definitive Validation:

  • Use RNA interference (siRNA/shRNA) to knockdown SLC38A6 expression

  • Create overexpression systems with tagged SLC38A6 for positive controls

  • When available, use tissue from genetic knockout models as the ultimate specificity control

These methodological strategies have been successfully employed in published research to ensure antibody specificity and minimize cross-reactivity issues when studying SLC38A6.

What are the best approaches for studying SLC38A6 in different model systems?

Different experimental model systems offer unique advantages for studying SLC38A6 function. Here are optimized approaches for various model systems:

• Mouse Models:

  • Genetic Knockout Models: Both systemic SLC38A6 knockout and conditional knockouts (e.g., Lyz-CRE for myeloid cells) have been successfully employed

  • Disease Models: LPS-induced sepsis models have been used to study SLC38A6's role in inflammation

  • Tissue Analysis: Immunohistochemistry on paraffin-embedded mouse brain tissues (7 μm thickness) has been effective for studying neuronal expression

  • Antibody Recommendations: Multiple antibodies have shown cross-reactivity with mouse SLC38A6, including PACO37902

• Cell Line Models:

  • Neuronal Studies: Primary neuronal cultures or neuronal cell lines for studying neuronal expression and function

  • Macrophage Studies: RAW264.7 cells have been successfully used for SLC38A6 overexpression studies using lentiviral vectors (pLJM-hSLC38A6-v2)

  • Expression Verification: Western blotting with anti-FLAG antibodies has been used to confirm successful overexpression

• Human Samples:

  • Patient Blood: Analysis of SLC38A6 expression in blood samples from patients with conditions like pneumonia

  • Correlation Studies: Relating SLC38A6 expression to clinical parameters such as monocyte counts and white blood cell numbers

• Methodological Considerations for Each Model:

  • For Protein Localization: Confocal microscopy at 63X magnification provides detailed subcellular information

  • For Protein Interactions: Proximity Ligation Assay (PLA) has been effective for studying SLC38A6 interactions with other proteins

  • For Functional Studies: Conditional knockout approaches allow tissue-specific investigation of SLC38A6 function

  • For Expression Analysis: Flow cytometry works well for analyzing SLC38A6 in specific immune cell populations

By selecting the appropriate model system and methodological approach, researchers can effectively investigate different aspects of SLC38A6 biology, from cellular expression patterns to functional roles in disease states.

How can researchers quantitatively analyze SLC38A6 expression levels in complex samples?

Quantitative analysis of SLC38A6 expression in complex biological samples requires rigorous methodological approaches. Here are optimal strategies for different sample types:

• Protein-Level Quantification:

  • Western Blot Densitometry:

    • Use standard curves with recombinant SLC38A6 protein for absolute quantification

    • Normalize to appropriate housekeeping proteins (e.g., β-actin for total protein, Na+/K+ ATPase for membrane proteins)

    • Expected band size between 37-50 kDa, with the theoretical size being 50-58 kDa

  • ELISA-Based Quantification:

    • Commercial SLC38A6 antibodies have been validated for ELISA at dilutions of 1:2000-1:10000

    • Develop standard curves using recombinant SLC38A6 protein

• Cellular Distribution Quantification:

  • Immunofluorescence Analysis:

    • Determine the percentage of SLC38A6-positive cells among specific cell populations

    • Example quantification approach: Count VIAAT/VGAT positive cells (inhibitory neurons) expressing SLC38A6 and compare with total cell numbers

    • In published studies, quantification has shown that while most excitatory neurons express SLC38A6, only a subset of inhibitory neurons do

• Subcellular Distribution Analysis:

  • Proximity Ligation Assay (PLA) Quantification:

    • Count PLA signals per cell to quantify protein-protein interactions

    • Published data has shown approximately 6-8 signals per cell for SLC38A6 interactions with synaptic proteins like Snap25 and Synaptotagmin

• Gene Expression Analysis:

  • RT-qPCR: For mRNA expression quantification, with appropriate reference genes

  • RNA-Seq: For transcriptome-wide analysis, allowing comparison of SLC38A6 expression across different conditions

• Population-Level Analysis in Mixed Samples:

  • Flow Cytometry: Particularly useful for quantifying SLC38A6 expression in specific immune cell populations in blood or tissue samples

  • Single-Cell RNA-Seq: For high-resolution analysis of SLC38A6 expression patterns in heterogeneous tissues

• Analysis in Disease Models:

  • Correlation Analysis: In clinical samples, correlate SLC38A6 expression with disease parameters

  • Example: In pneumonia patients, SLC38A6 expression has been shown to correlate with monocyte numbers and white blood cell counts

These quantitative approaches have been successfully employed in research studies and provide robust methods for analyzing SLC38A6 expression across different experimental contexts and sample types.